Leadman(SZ:300289) Zhong Guo Jing Ji Wang·2025-07-31 06:27Core Viewpoint - Lidman (300289.SZ) announced a significant asset restructuring plan, intending to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, which has led to a stock price surge of 19.93% to 7.04 yuan [1][2]. Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as per the regulations, and it will not involve issuing new shares or result in a change of control [2][3]. - The funding for the acquisition will come from the company's own funds and bank merger loans [2][3]. - The framework agreement for the acquisition was signed on July 30, 2025, and the company did not hold any shares in the target company prior to this transaction [1][2]. Group 2: Financial Performance - In 2024, the company reported a revenue of 370.23 million yuan, a decrease of 19.79% compared to 2023 [3][4]. - The net profit attributable to shareholders was -75.10 million yuan, a decline of 589.66% from the previous year [3][4]. - The net cash flow from operating activities was 62.41 million yuan, down 52.29% year-on-year [3][4]. Group 3: Recent Quarterly Performance - For Q1 2025, the company reported a revenue of 78.91 million yuan, a decrease of 16.61% year-on-year [4]. - The net profit attributable to shareholders was -1.25 million yuan, an improvement of 53.73% compared to the same period last year [4]. - The net cash flow from operating activities for Q1 2025 was 10.69 million yuan, an increase of 25.64% year-on-year [4].